IP 501

Drug Profile

IP 501

Latest Information Update: 19 Sep 2003

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Department of Veterans Affairs; Indevus Pharmaceuticals; National Institutes of Health (USA); Nonindustrial source
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Liver disorders

Most Recent Events

  • 17 May 2003 Discontinued - Phase-III for Liver disorders in South Korea (PO)
  • 17 May 2003 Discontinued - Phase-III for Liver disorders in Europe (PO)
  • 17 May 2003 Discontinued - Phase-III for Liver disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top